- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07671599
Perioperative Use of Continuous Glucose Monitoring for Scheduled Cesarean Deliveries (PERUSE) (PERUSE)
Perioperative Use of Continuous Glucose Monitoring for Scheduled Cesarean Deliveries (PERUSE): A Pilot Study
This prospective pilot study is exploratory in nature and is designed to evaluate the validity of continuous glucose monitor (CGM) use for perioperative glucose surveillance during scheduled Cesarean delivery for nondiabetic patients. Primary objective is characterization of perioperative glucose trends during elective Cesarean delivery in patients without diabetes and exploratory analyses will describe perioperative glucose patterns captured by CGM. Secondary objective is to examine rates of and associations with post-operative complications, including surgical site infections.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Nicola F Tavella, MPH
- Telefonnummer: (212) 241-3888
- E-post: nicola.tavella@mssm.edu
Studera Kontakt Backup
- Namn: Kavya Shivashankar, MD
- Telefonnummer: (212) 241-5681
- E-post: kavya.shivashankar@mssm.edu
Studieorter
-
-
New York
-
New York, New York, Förenta staterna, 10029
- Rekrytering
- Icahn School of Medicine at Mount Sinai
-
Kontakt:
- Nicola F Tavella, MPH
- Telefonnummer: 2122413888
- E-post: nicola.tavella@mssm.edu
-
Huvudutredare:
- Angela Bianco
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
continuous glucose monitor (CGM) use for perioperative glucose surveillance during scheduled Cesarean delivery for nondiabetic patients
Beskrivning
Inclusion Criteria:
- singleton pregnancy
- no prior diagnosis of diabetes (gestational included)
- scheduled term cesarean delivery in Mount Sinai Health System
- aged 18-50 years
Exclusion Criteria:
- preexisting diabetes mellitus
- diagnosis of gestational diabetes mellitus (GDM) in the current pregnancy, based on standard prenatal screening
- known endocrine disorder affecting glucose metabolism (such as Cushing syndrome, poorly controlled thyroid disorder, etc.)
- use of antenatal steroids within the two weeks prior to delivery
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
scheduled term c-section
Patients scheduled for term cesarean deliveries and who are screened eligible and consented will be administered a continuous glucose monitor prior to their c-section, and they will wear the device through their stay in the hospital. |
Continuous glucose monitor during perioperative Cesarean delivery |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
interstitial glucose from CGM device
Tidsram: from pre-operative appointment through end of postpartum hospital stay, up to ten days
|
glucose of interstitial fluid as measured by CGM device on participant's arm |
from pre-operative appointment through end of postpartum hospital stay, up to ten days
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of surgical site infection
Tidsram: Post-op through end of postpartum hospital say, up to ten days.
|
Diagnosis of surgical site infection as a measure of post-operative complications |
Post-op through end of postpartum hospital say, up to ten days.
|
Samarbetspartners och utredare
Utredare
- Huvudutredare: Angela Bianco, MD, Faculty
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- STUDY-26-00229
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
All of the individual participant data collected during the trial, after deidentification.
Tidsram för IPD-delning
Immediately following publication. No end date.
Kriterier för IPD Sharing Access
Researchers who provide a methodologically sound proposal. To achieve aims in the approved proposal. Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in the University's data warehouse but without investigator support other than deposited metadata. Information regarding submitting proposals and accessing data may be found at (Link tbd).
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- ICF
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .